Current status and future perspectives of patient-reported outcome research in clinical trials for patients with breast cancer in Japan.
Current status and future perspectives of patient-reported outcome research in clinical trials for patients with breast cancer in Japan.
复制标题
日本乳腺癌患者临床试验中患者报告结果研究的现状和未来前景。
DOI:
10.1007/s12282-012-0368-8
复制
发表时间:
2013
期刊:
影响因子:
4
通讯作者:
Shimozuma K
中科院分区:
文献类型:
--
作者:
Ohsumi S;Shimozuma K
The aim of healthcare providers is to help patients regain their health and/or maintain or increase their happiness. The quality of healthcare can be assessed objectively by using indices such as survival rates, but subjective assessment is sometimes more important than objective evaluation, because whether patients feel healthy or happy or not is their major concern. Quality of life (QOL) research is a typical approach to subjective assessment of health. Self-administered health-related QOL (HRQOL) questionnaires are used to obtain patient-reported outcome (PRO) data. PRO is defined by the US Food and Drug Administration (FDA) as any report of the status of a patient’s health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else. PRO data are regarded as more accurate than clinician-rated ones in terms of assessing patients’ symptoms and HRQOL. The Comprehensive Support Project for Health Outcome Research of the Public Health Research Foundation has conducted much PRO research in collaboration with the Comprehensive Support Project for Oncology Research, especially in randomized controlled trials (RCTs). Here, we review the results of PRO research in RCTs conducted in Japan and examine future perspectives in this field.